The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients

Clinical Transplantation

Volumn 17, Issue 3, 2003, Pages 234-241

  Kuypers, Dirk R J ^a   Evenepoel, P ^a   Maes, B ^a   Coosemans, W ^a   Pirenne, J ^a   Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anti CD25 monoclonal antibody; Calcineurine inhibitor; Graft function; Low dose tacrolimus; Nephrotoxicity

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CORTICOSTEROID; CREATININE; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS; DIALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; RECIPIENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-2; TACROLIMUS;

EID: 0038001505     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00038.x     Document Type: Article

References (24)

1. Gareth P, Bruno M, Gregorio RB. The clinical impact of cyclosporine nephrotoxicity in heart transplantation. Transplantation 2000: 69 (suppl.): SS23.
2. Zietse R, Balk AH, Dorpel MA et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994: 14: 1.
3. Fischer NC, Nightingale PG, Gunson BK et al. Chronic renal failure following liver transplantation. Transplantation 1998: 66: 59.
4. Dieterle A, Gratwohl A, Nizze H et al. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990: 49: 1093.
5. Groth CG, Bäckman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999: 67: 1036.
6. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.
7. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.
8. Wauters JP, Rosman JB, Descombes A et al. Ten-year experience with low-dose cyclosporine A in renal transplantation. Transplant Proc 1994: 26: 2528.
9. Solez K, Vincenti F, Filo RS et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998: 66: 1736.
10. Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and neoral in renal transplant recipients: an interim report. Transplant Proc 1999: 31: S64.
11. Hutchinson IV. The role of transforming growth factor-β in transplant rejection. Transplant Proc 1999: 31: S9.
12. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
13. Vanrenterghem Y, Squiet JP, Forsythe J et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. Transplant Proc 1998: 30: 1290.
14. Miller J for the FK506/MMF Dose-Ranging Kidney Transplant Study Group. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. Transplant Proc 1999: 31: 276.
15. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year acturial follow-up. Transplant Proc 1999: 31: 1134.
16. Yang HC, Holman MJ, Langho E et al. Tacrolimus/'low-dose' mycophenolate mofetil versus microemulsion cyclosporine/'low-dose' mycophenolate mofetil after kidney transplantation - 1-year follow-up of a prospective, randomized clinical trial. Transplant Proc 1999: 31: 1121.
17. Kahan BD, Julian BA, Pescovitz MD. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allograft: a phase II trial. Rapamune Study Group. Transplantation 1999: 68: 1526.
18. Vitko S, Margreiter R, Weimar W et al. International, double-blind, parallel group study of the safety and efficacy of Certican (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and steroids. Am J Transplantation 2001: 1 (suppl. 1): 474 (abstract #1337).
19. Tedesco H, Kahan B, Mourad G et al. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients (interim data). Am J Transplantation 2001: 1 (suppl. 1): 243. (abstract #429)
20. Ciancio G, Miller A, Burke GW et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil and steroids as maintenance immunosuppression. Transplant Proc 2001: 33: 1013.
21. Mclaren AJ, Jassem W, Gray DW et al. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999: 13: 266.
22. Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261.
23. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997: 5: 225.
24. Squiet JP, Bäckman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001: 72: 63.